Effects of hypoxia on human cancer cell line chemosensitivity
暂无分享,去创建一个
Mårten Fryknäs | Rolf Larsson | Sara Strese | R. Larsson | M. Fryknäs | J. Gullbo | Joachim Gullbo | Sara Strese
[1] J. Brown,et al. Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.
[2] C. Koch,et al. Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation , 2001, American journal of clinical oncology.
[3] Shuang-yin Han,et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. , 2008, Cancer science.
[4] S. Wilhelm,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.
[5] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[6] B. Teicher,et al. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. , 1981, Cancer research.
[7] A. Sartorelli,et al. Generation of Oxygen Deficiency in Cell Culture Using a Two-Enzyme System to Evaluate Agents Targeting Hypoxic Tumor Cells , 2008, Radiation research.
[8] J. Raleigh,et al. Identification of nonproliferating but viable hypoxic tumor cells in vivo. , 1998, Cancer research.
[9] J. Siegfried,et al. Effects of anthracyclines on oxygenated and hypoxic tumor cells. , 1983, Cancer research.
[10] H. S. Schwartz. Pharmacology of mitomycin C. III. In vitro metabolism by rat liver. , 1962, The Journal of pharmacology and experimental therapeutics.
[11] A. Matsumura,et al. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells , 2005, Journal of Cancer Research and Clinical Oncology.
[12] S. Steinberg,et al. Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors , 2011, Clinical Cancer Research.
[13] S. Gamage,et al. Structure−Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine , 2003 .
[14] P. Vaupel,et al. Treatment resistance of solid tumors: role of hypoxia and anemia. , 2001, Medical oncology.
[15] M. Sekine,et al. Vascular Endothelial Growth Factor Mediates Intracrine Survival in Human Breast Carcinoma Cells through Internally Expressed VEGFR1/FLT1 , 2007, PLoS medicine.
[16] Peter Nygren,et al. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) , 1992, International journal of cancer.
[17] D. Scudiero,et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.
[18] M. Dewhirst,et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] S. Yang,et al. Cobalt chloride-induced apoptosis and extracellular signal-regulated protein kinase 1/2 activation in rat C6 glioma cells. , 2004, Journal of biochemistry and molecular biology.
[20] David E. Housman,et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.
[21] Corinne E Griguer,et al. Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. , 2006, Cancer research.
[22] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[23] Liz Y. Han,et al. Functional significance of VEGFR‐2 on ovarian cancer cells , 2009, International journal of cancer.
[24] Huafeng Zhang,et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.
[25] B. Zetter,et al. Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.
[26] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] C. Schmitt,et al. Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB , 2010, PloS one.
[28] K. Brennan,et al. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. , 2012, Urologic oncology.
[29] Meenhard Herlyn,et al. Axis of evil: molecular mechanisms of cancer metastasis , 2003, Oncogene.
[30] M. Gaub,et al. Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis , 2009, Clinical Cancer Research.
[31] I. Roninson. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. , 1992, Biochemical pharmacology.
[32] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[33] M. Gassmann,et al. Regulation of the multidrug resistance transporter P‐glycoprotein in multicellular tumor spheroids by hypoxia‐inducible factor‐1 and reactive oxygen species , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] J. Dorsman,et al. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. , 2007, Biochemical pharmacology.
[35] C. Graham,et al. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1 , 2009, Molecular Cancer Therapeutics.
[36] Jae-hoon Park,et al. The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells , 2009, BMC Cancer.
[37] B. Brüne,et al. Tumor hypoxia and cancer progression. , 2006, Cancer letters.
[38] T. Danielsen,et al. Hypoxia-induced changes in radiation sensitivity in human melanoma cells: importance of oxygen-regulated proteins, adenylate energy charge and cell cycle distribution. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[39] L. Kunz-Schughart,et al. Multicellular tumor spheroids: an underestimated tool is catching up again. , 2010, Journal of biotechnology.
[40] T. Cramer,et al. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[41] N. Masumori,et al. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. , 2008, Biomedical research.
[42] M. Kunitama,et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan , 2009, Molecular Cancer Therapeutics.
[43] Janice M. Y. Brown,et al. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.
[44] Elin Lindhagen,et al. The fluorometric microculture cytotoxicity assay , 2008, Nature Protocols.
[45] J. Pouysségur,et al. Hypoxia and cancer , 2007, Journal of Molecular Medicine.
[46] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[47] Christian Sillaber,et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. , 2002, Blood.
[48] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[49] A. Eggermont,et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.
[50] C. Aquino-Parsons,et al. A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. , 2001, International journal of radiation oncology, biology, physics.
[51] H. Esumi,et al. Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs , 2011, Cancer science.
[52] Jun O. Liu,et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.
[53] Kwangmo Yang,et al. The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression , 2013, Oncology reports.
[54] L. Huang,et al. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. , 2008, Blood.
[55] P. Giannakakou,et al. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. , 2005, Cancer research.
[56] A. Giaccia,et al. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.
[57] C. Grau,et al. The relationship between carbon monoxide breathing, tumour oxygenation and local tumour control in the C3H mammary carcinoma in vivo. , 1994, British Journal of Cancer.
[58] S. Williamson,et al. Tirapazamine: a novel agent targeting hypoxic tumor cells. , 2009, Expert opinion on investigational drugs.
[59] P Vaupel,et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.
[60] Shuang-yin Han,et al. Hypoxia‐inducible factor‐1α contributes to hypoxia‐induced chemoresistance in gastric cancer , 2007 .
[61] C. Koch,et al. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. , 1995, British Journal of Cancer.
[62] H. S. Schwartz,et al. Pharmacology of mitomycin C. I. Toxicity and pathologic effects. , 1960, Cancer research.
[63] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[65] Jiannis Ragoussis,et al. Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition , 2006, Journal of Biological Chemistry.
[66] W. Figg,et al. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. , 1998, Biochemical pharmacology.
[67] Y. Abe,et al. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer. , 2011, Oncology reports.
[68] R. Cardone,et al. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis , 2005, Nature Reviews Cancer.
[69] B. Telfer,et al. Hypoxia‐targeted over‐expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT‐11) , 2007, The journal of gene medicine.
[70] I. Olver,et al. Tirapazamine: from bench to clinical trials. , 2006, Current clinical pharmacology.
[71] Christine C. Hudson,et al. Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.
[72] K. Kihara,et al. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids , 2004, Molecular and Cellular Endocrinology.
[73] Franz Rachbauer,et al. Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. , 2002, Radiology.
[74] T. E. Fitzpatrick,et al. Effect of hypoxia on cellular adhesion to vitronectin and fibronectin. , 2001, Biochemical and biophysical research communications.
[75] T. Kwok,et al. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. , 1991, British Journal of Cancer.
[76] C. Bokemeyer,et al. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro , 2003, British Journal of Cancer.
[77] R. Larsson,et al. Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. , 2012, Experimental cell research.
[78] D. Ribatti,et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.
[79] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[80] Crispin J. Miller,et al. Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance , 2004, Molecular and Cellular Biology.
[81] F. de Longueville,et al. Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity , 2008, Molecular Cancer.